Pharsight

Probuphine patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7736665 TITAN PHARMS Implantable polymeric device for sustained release of buprenorphine
Apr, 2024

(a month ago)

Probuphine is owned by Titan Pharms.

Probuphine contains Buprenorphine Hydrochloride.

Probuphine has a total of 1 drug patent out of which 1 drug patent has expired.

Expired drug patents of Probuphine are:

  • US7736665

Probuphine was authorised for market use on 26 May, 2016.

Probuphine is available in implant;implantation dosage forms.

Probuphine can be used as for opioid dependence.

The generics of Probuphine are possible to be released after 25 April, 2024.

Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) May 26, 2019

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

Drugs and Companies using BUPRENORPHINE HYDROCHLORIDE ingredient

Market Authorisation Date: 26 May, 2016

Treatment: For opioid dependence

Dosage: IMPLANT;IMPLANTATION

More Information on Dosage

PROBUPHINE family patents

Family Patents